当前位置: 首页 >> 检索结果
381. Sex-dependent impact of OSA on digital vascular function.
作者: Anna Randby.;Silje K Namtvedt.;Harald Hrubos-Strøm.;Gunnar Einvik.;Virend K Somers.;Torbjørn Omland.
来源: Chest. 2013年144卷3期915-922页
Indexes of associations between OSA and impaired vascular function are mainly based on small, clinic-based studies of conduit artery function in men with severe sleep apnea. Larger population-based studies show no independent associations or associations in women only. Sex differences in OSA-related mortality may exist, and sex differences in vascular function in subjects with OSA need to be explored. We, therefore, assessed whether OSA is associated with digital vascular function in a large population-based sample and whether this association is influenced by sex.
382. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.
作者: Ivan F N Hung.;Kelvin K W To.;Cheuk-Kwong Lee.;Kar-Lung Lee.;Wing-Wa Yan.;Kenny Chan.;Wai-Ming Chan.;Chun-Wai Ngai.;Kin-Ip Law.;Fu-Loi Chow.;Raymond Liu.;Kang-Yiu Lai.;Candy C Y Lau.;Shao-Haei Liu.;Kwok-Hung Chan.;Che-Kit Lin.;Kwok-Yung Yuen.
来源: Chest. 2013年144卷2期464-473页
Experience from influenza pandemics suggested that convalescent plasma treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust treatment data are lacking.
383. The Epworth Sleepiness Scale: conventional self vs physician administration.
作者: Mario Francesco Damiani.;Vitaliano Nicola Quaranta.;Vito Antonio Falcone.;Felice Gadaleta.;Michele Maiellari.;Teresa Ranieri.;Francesco Fanfulla.;Pierluigi Carratù.;Onofrio Resta.
来源: Chest. 2013年143卷6期1569-1575页
The Epworth Sleepiness Scale (ESS) is a simple, self-administered questionnaire that provides a measurement of the subject's level of daytime sleepiness, and is widely used for patients with obstructive sleep apnea (OSA). Some works undermined its accuracy. The aim of this study was to compare self-administered ESS scores to physician-administered scores in a sample of patients with suspicion of OSA.
384. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
作者: Diana Bilton.;Evangelia Daviskas.;Sandra D Anderson.;John Kolbe.;Gregory King.;Rob G Stirling.;Bruce R Thompson.;David Milne.;Brett Charlton.; .
来源: Chest. 2013年144卷1期215-225页
Inhaled dry powder mannitol enhanced mucus clearance and improved quality of life over 2 weeks in non-cystic fibrosis bronchiectasis. This study's objective was to investigate the efficacy and safety of dry powder mannitol over 12 weeks.
385. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
作者: Steven M Rowe.;Ginger Reeves.;Heather Hathorne.;G Martin Solomon.;Smita Abbi.;Didier Renard.;Ruth Lock.;Ping Zhou.;Henry Danahay.;John P Clancy.;David A Waltz.
来源: Chest. 2013年144卷1期200-207页
Prostasin, a trypsin-like serine protease, is a channel-activating protease and major regulator of epithelial sodium channel-mediated sodium absorption. Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF).
386. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.
作者: William B White.;Glen E Cooke.;Peter R Kowey.;Peter M A Calverley.;Dirk Bredenbröker.;Udo-Michael Goehring.;Haiyuan Zhu.;Hassan Lakkis.;Hans Mosberg.;Paul Rowe.;Klaus F Rabe.
来源: Chest. 2013年144卷3期758-765页
Evaluation of cardiovascular safety for new therapies for COPD is important because of a high prevalence of cardiac comorbidities in the COPD population. Hence, we evaluated the effects of roflumilast, a novel oral phosphodiesterase 4 inhibitor developed for the treatment and prevention of COPD exacerbations, on major adverse cardiovascular events (MACEs).
387. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.
作者: Gianluca Campo.;Paolo Guastaroba.;Antonio Marzocchi.;Andrea Santarelli.;Elisabetta Varani.;Luigi Vignali.;Pietro Sangiorgio.;Stefano Tondi.;Carlotta Serenelli.;Rossana De Palma.;Francesco Saia.
来源: Chest. 2013年144卷3期750-757页
There are limited data describing the long-term outcome of patients with concomitant COPD who develop ST-segment elevation myocardial infarction (STEMI).
388. Effects of experimental sleep restriction on caloric intake and activity energy expenditure.
作者: Andrew D Calvin.;Rickey E Carter.;Taro Adachi.;Paula G Macedo.;Felipe N Albuquerque.;Christelle van der Walt.;Jan Bukartyk.;Diane E Davison.;James A Levine.;Virend K Somers.
来源: Chest. 2013年144卷1期79-86页
Epidemiologic studies link short sleep duration to obesity and weight gain. Insufficient sleep appears to alter circulating levels of the hormones leptin and ghrelin, which may promote appetite, although the effects of sleep restriction on caloric intake and energy expenditure are unclear. We sought to determine the effect of 8 days/8 nights of sleep restriction on caloric intake, activity energy expenditure, and circulating levels of leptin and ghrelin.
389. Arm elevation and coordinated breathing strategies in patients with COPD.
作者: Thomas E Dolmage.;Tania Janaudis-Ferreira.;Kylie Hill.;Shirley Price.;Dina Brooks.;Roger S Goldstein.
来源: Chest. 2013年144卷1期128-135页
Hyperinflated patients with COPD breathe against an increased elastic load during physical activity. Arm activities are especially demanding. Some pulmonary rehabilitation programs instruct patients to inhale while raising their arms, whereas others recommend the opposite. This study aimed to determine the effect of coordinating breathing with arm movements on the endurance of a lifting task.
390. Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS.
We hypothesized that nebulized iloprost would improve ventilation-perfusion matching in patients with pulmonary hypertension and ARDS as reflected by an improved Pao2/Fio2 ratio and Pao2 without adversely affecting lung mechanics or systemic hemodynamics.
391. Interobserver variability in grading transbronchial lung biopsy specimens after lung transplantation.
作者: Sangeeta M Bhorade.;Aliya N Husain.;Chuanhong Liao.;Lee Chuan Li.;Vivek N Ahya.;Maher A Baz.;Vincent G Valentine.;Robert B Love.;Harish Seethamraju.;Charles G Alex.;Remzi Bag.;Nilto C DeOliveira.;Wickii T Vigneswaran.;Edward R Garrity.;Selim M Arcasoy.
来源: Chest. 2013年143卷6期1717-1724页
Acute rejection remains a major source of morbidity after lung transplantation. Given the importance of this diagnosis, an international grading system was developed to standardize the diagnosis of acute lung-allograft rejection. The reliability of this grading system has not been adequately assessed by previous studies.
392. Optimizing the 6-min walk test as a measure of exercise capacity in COPD.
作者: Divay Chandra.;Robert A Wise.;Hrishikesh S Kulkarni.;Roberto P Benzo.;Gerard Criner.;Barry Make.;William A Slivka.;Andrew L Ries.;John J Reilly.;Fernando J Martinez.;Frank C Sciurba.; .
来源: Chest. 2012年142卷6期1545-1552页
It is uncertain whether the effort and expense of performing a second walk for the 6-min walk test improves test performance. Hence, we attempted to quantify the improvement in 6-min walk distance if an additional walk were to be performed.
393. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial.
作者: William J Anderson.;Philip M Short.;Peter A Williamson.;Brian J Lipworth.
来源: Chest. 2012年142卷6期1553-1561页
International guidelines advocate a standard approach to asthma management for all, despite its heterogeneity. "Personalized" treatment of inflammatory asthma phenotypes confers superior benefits. We wished to evaluate dose response to inhaled corticosteroids (ICSs) in patients with asthma with an elevated fractional exhaled nitric oxide (Feno) phenotype using domiciliary measurements.
394. Airway vascular endothelial function in healthy smokers without systemic endothelial dysfunction.
作者: Eliana S Mendes.;Jose Eduardo D Cancado.;Patricia Rebolledo.;Joahna Arana.;Meela Parker.;Alex Gonzalez.;Barry E Hurwitz.;Adam Wanner.
来源: Chest. 2013年143卷6期1733-1739页
Cigarette smoking can lead to systemic endothelial dysfunction. Since the airway circulation is exposed to a high concentration of cigarette smoke constituents, we reasoned that airway vascular endothelial dysfunction could be present in healthy smokers without systemic endothelial dysfunction.
395. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
作者: Hoi Nam Tse.;Luca Raiteri.;King Ying Wong.;Kwok Sang Yee.;Lai Yun Ng.;Ka Yan Wai.;Ching Kong Loo.;Ming Houng Chan.
来源: Chest. 2013年144卷1期106-118页
The mucolytic and antioxidant effects of N-acetylcysteine (NAC) may have great value in COPD treatment. However, beneficial effects have not been confirmed in clinical studies, possibly due to insufficient NAC doses and/or inadequate outcome parameters used. The objective of this study was to investigate high-dose NAC plus usual therapy in Chinese patients with stable COPD.
396. Does autotitrating positive airway pressure therapy improve postoperative outcome in patients at risk for obstructive sleep apnea syndrome? A randomized controlled clinical trial.
Obstructive sleep apnea has been associated with postoperative complications. We hypothesized that postoperative autotitrating positive airway pressure (APAP) applied to patients at high risk for obstructive sleep apnea would shorten hospital stay and reduce postoperative complications.
397. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial.
作者: Klaus F Rabe.;Leonardo M Fabbri.;Claus Vogelmeier.;Harald Kögler.;Hendrik Schmidt.;Kai M Beeh.;Thomas Glaab.
来源: Chest. 2013年143卷3期711-719页
There is still a lack of data on the seasonality of exacerbations of COPD based on large randomized studies using COPD exacerbations as primary end points. The objective of this study was to assess the seasonal pattern of moderate and severe exacerbations and analyze the influence of associated baseline factors. We also determined the timing of second exacerbations and the potential impact of the 2009 influenza A(H1N1) pandemic on exacerbations.
398. Impact of lung transplantation on recipient quality of life: a serial, prospective, multicenter analysis through the first posttransplant year.
作者: C Ashley Finlen Copeland.;David M Vock.;Karen Pieper.;Daniel B Mark.;Scott M Palmer.
来源: Chest. 2013年143卷3期744-750页
Quality of life (QOL) is an important but understudied outcome after lung transplantation. Previous cross-sectional, single-center studies suggest improved QOL, but few prior longitudinal multicenter data exist regarding the effect of transplantation on the patient’s QOL.
399. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
作者: Nicola Fazio.;Dan Granberg.;Ashley Grossman.;Stephen Saletan.;Judith Klimovsky.;Ashok Panneerselvam.;Edward M Wolin.
来源: Chest. 2013年143卷4期955-962页
The incidence of neuroendocrine tumors (NETs) has increased approximately fivefold since the 1980s. A similar increase in the incidence of lung NETs has been reported, but therapy has not been optimized.
400. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.
作者: Daniel J Weiss.;Richard Casaburi.;Robin Flannery.;Michelle LeRoux-Williams.;Donald P Tashkin.
来源: Chest. 2013年143卷6期1590-1598页
COPD is a devastating disease affecting millions worldwide. As disease pathogenesis includes both chronic pulmonary and systemic inflammation, antiinflammatory effects of systemically administered mesenchymal stem cells (MSCs) may decrease inflammation, resulting in improved lung function and quality of life. The goal of this study was to assess safety and to perform an initial evaluation of the potential efficacy of systemic MSC administration to patients with moderate to severe COPD.
|